Cipla has partnered with Stempeutics Research to launch Ciplostem, a therapy for Knee Osteoarthritis, approved by the Drug Controller General of India (DCGI). Developed by Stempeutics Research, the therapy offers a disease-modifying treatment option targeting Grade II and III Knee OA and marks a significant advancement in Cipla's entry into Orthobiologic medicine.
Through this launch, Cipla and Stempeutics reaffirm their collective focus on science- driven progress in chronic disease management, offering a next-generation joint preservation therapy aimed at improving patients’ everyday lives.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
